Navigation Links
PAREXEL Reports Second Quarter Fiscal Year 2011 Financial Results
Date:1/31/2011

nths ended December 31, 2010 was $34.7 million, or $0.58 per diluted share, compared with $27.6 million or $0.47 per diluted share in the comparable prior year six month period.

Backlog at the end of December was approximately $3.0 billion, an increase of 30.9% year-over-year.  Backlog included gross new business wins in the quarter of $496.0 million, cancellations of $100.4 million (3.4% of beginning backlog), and a positive impact from foreign exchange rates of $3.7 million. The net book-to-bill ratio was 1.30 in the quarter.

Mr. Josef H. von Rickenbach, PAREXEL’s Chairman and Chief Executive Officer stated, “During the second quarter, PAREXEL delivered year-over-year revenue growth in all three business segments, and earnings per share that were in line with our expectations.  New business wins and moderate cancellations culminated in record backlog of over $3 billion.  We also experienced a notable increase in proposals from small and emerging biopharma clients during the quarter.”  

“PAREXEL’s global capabilities, expertise, and technology continue to enable us to win healthy new business awards.  At the same time, it has become apparent that the backlog conversion rates inherent in global, complex, clinical development awards generated by strategic partnerships are different from traditional awards.  Our improved understanding of new business dynamics from these partnerships has been reflected in our current forward-looking guidance.”

“As we enter Calendar Year 2011, we are confident in our strategy and that PAREXEL is positioned as a leader in a changing marketplace.  I believe that we have the foundation in place to achieve long-term revenue and earnings growth, and that we will continue to create and deliver value to clients and shareholders.”

The Company issued forward-looking guidance for the third quarter of Fiscal Year 2011 (ending March
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. PAREXEL Announces Date of Second Quarter Fiscal Year 2011 Earnings Release and Conference Call
2. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
3. PAREXEL Announces Date of First Quarter Fiscal Year 2011 Earnings Release and Conference Call
4. PAREXEL Issues Updated Financial And Operational Information
5. PAREXEL Consulting Releases New Study Data on Drug Development Timelines in Safety First Era
6. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
7. PAREXEL International to Present at Robert Baird 2009 Healthcare Conference
8. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2009 Earnings Release and Conference Call
9. PAREXEL International to Present at the Wachovia Equity Conference
10. PAREXEL Experts to Present Leading Insights at Drug Information Association 45th Annual Meeting
11. PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... DALLAS , September 29, 2014 /PRNewswire/ ... market research report "Epigenetics Market by Product (Modifying ... Consumables, Kit, Bisulphite Conversion Kit, Reagents), by ... User - Global Forecast to 2019", published ... the major drivers, restraints, opportunities, current market ...
(Date:9/29/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: ... proprietary technologies and products for advanced microarray diagnostics, is ... to Chairman of the Board of Directors of ... continue to serve as a Director on the Board ... "We are very pleased to have ...
(Date:9/29/2014)... , Sept. 29, 2014  Perrigo Company plc ... that it has transferred a portfolio of preclinical ... 2013 acquisition of Elan Corporation plc, to drug ... of the agreement, Perrigo will receive an upfront ... and royalties on any future sales derived from ...
(Date:9/28/2014)... Boston, Mass. (PRWEB) September 29, 2014 ... delivers integrated cold chain management solutions for highly ... Brian Brazill, will present the company’s Advantage Transport ... Chain GDP & Temperature Management Logistics Global Forum ... will explain and demonstrate the company’s lab software ...
Breaking Biology Technology:Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4SQI Diagnostics Announces New Chairman of Board of Directors 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 3Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 4Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 2Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 3
... PARSIPPANY, N.J., Sept. 1, 2011 New data, published ... the long-term safety and tolerability of FIRMAGON ® ... cancer when used over three years.(1) The new study ... III study (CS21) in which FIRMAGON ® was ...
... BRUSSELS, September 1, 2011 The current ... successful research into blood-related diseases must ensure the safety ... This was a key message of a ... by the European Parliament and attended by doctors, researchers, ...
... September 1, 2011 The medical imaging ... has secured an order for their magnetic resonance imaging ... The software will be used in clinical practice to ... The software, SyMRI Diagnostics, includes tools to automatically ...
Cached Biology Technology:New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 2New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 3New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 4New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 5New Data on Long-Term Use of FIRMAGON® (degarelix for injection) for Advanced Hormone-Dependant Prostate Cancer Published in Journal of Urology 6Crucial Directives Must be Revised to Protect Patients' Interests and Improve Access to Treatment 2Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 2Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation 3
(Date:9/29/2014)... President Juan Manuel Santos has presented Dr. Cristin ... Society, with the prestigious Order of San Carlos. ... citizens, foreign civilians and military officers who have ... the field of international relations. , An international ... Samper was invited to the Colombian Residence in ...
(Date:9/29/2014)... deemed inaccessible or esoteric. Yet in the modern world, ... daily lives and a decisive role in the discovery ... scenes. , UC Santa Barbara,s Paul Atzberger, a professor ... of mechanical engineering, often works in areas where science ... in the Proceedings of the National Academy of ...
(Date:9/29/2014)... a real-time feedback system together with a human energy ... reduction of 37% in energy consumption when compared to ... equivalent to a reduction of 713.71 kg of CO ... another eight halls, exposed only to the real-time feedback ... 3.5% reduction in energy consumption. , Student,s energy-use behaviour ...
Breaking Biology News(10 mins):At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4
... for the planet,s gravest health threats is hatched by ... new report sets out a 10-point plan for this ... flu. Ministers of health and agriculture will formulate ... the threat of avian flu and other emerging infectious ...
... Integrates with,Citrix Password Manager Single-Sign On Solution ... Oct. 22 Fujitsu Computer Products of,America, ... products including,hard disk drives, peripherals and biometric ... has been verified as Citrix,Ready(TM). The PalmSecure ...
... The leading cause of death in all cancer patients ... a form of treatment in which chemicals are used to ... biochemists that focuses on cancer cells reports that ingesting apigenin ... fruit improves cancer cells, response to chemotherapy. ...
Cached Biology News:Avian flu threat: New approach needed 2Fujitsu PalmSecure LOGONDIRECTOR Verified as Citrix Ready 2Fujitsu PalmSecure LOGONDIRECTOR Verified as Citrix Ready 3Fujitsu PalmSecure LOGONDIRECTOR Verified as Citrix Ready 4How eating fruit and vegetables can improve cancer patients' response to chemotherapy 2
Hamster Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels....
... Kit with CyScribe GFX Purification Kit, ... purification of Cy3- and Cy5-labeled cDNA.Optimized ... cDNA labeling and purification.Flexible and optimized ... labeling reactions with either Cy3- or ...
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Homo sapiens toll interacting protein Antigen: Recombinant Protein...
Biology Products: